Photo from Zack Armen/LinkedIn
May 9, 2024, 12:46
Zack Armen: A major transaction with Ligand Pharmaceuticals and Agenus
Zack Armen, Head of Investor Relations at Agenus, shared a post on LinkedIn:
”Yesterday we announced a major transaction with Ligand Pharmaceuticals, who committed $100M ($75M upfront) as part of a Royalty Financing agreement including six of our partnered programs + our lead combo asset, BOT/BAL. This transaction strengthens Agenus’ balance sheet and our strategic positioning as we head toward key development and regulatory inflection points in the BOT/BAL program.
We thank our new partners at Ligand for their support and shared conviction in BOT/BAL’s potential to help patients in need across the solid tumor landscape. Details of the transaction can be found here.”
Source: Zack Armen/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 13:49
Nov 14, 2024, 13:44
Nov 14, 2024, 13:37
Nov 14, 2024, 13:32
Nov 14, 2024, 13:29
Nov 14, 2024, 13:02
Nov 14, 2024, 12:44